A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Active not recruiting 607 enrolled AstraZeneca

RandomizedParallel-groupOpen-labelTreatment

Summary

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Timeline

Start: 2022-09-12
Primary completion: 2027-07-15
Completion: 2029-04-10

Publications

Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Oct;18(33):3689-3699. doi: 10.2217/fon-2022-0456. Epub 2022 Sep 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acalabrutinib	Small molecule	—	Oral
Subject	Obinutuzumab	Monoclonal antibody	—	Intravenous
Subject	Venetoclax	Small molecule	—	Oral

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Summary

Timeline

Publications

Drugs

Indications